Literature DB >> 24037912

Association between p53 Arg72Pro polymorphism and thyroid cancer risk: a meta-analysis.

Bo Wu1, Dan Guo, Ying Guo.   

Abstract

The p53 is a tumor suppressor gene which may be involved in the development of thyroid cancer. Studies investigating the association between p53 Arg72Pro polymorphism and thyroid cancer risk reported conflicting results. The aim of the meta-analysis was to derive a more precise assessment of the association between p53 Arg72Pro polymorphism and thyroid cancer risk. A literature search of PubMed and Web of Science from their inception through March 2013 was conducted. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to assess the strength of the association. Eight case-control studies were included with a total of 874 thyroid cancer cases and 1,891 controls. The meta-analysis results showed that the p53 Arg72Pro polymorphism was only associated with thyroid cancer risk under the recessive model (ProPro vs. ArgArg/ArgPro: OR = 1.83, 95% CI 1.05-3.20, P = 0.034). However, there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95% CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95% CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95% CI 0.66-1.55, P = 0.968). Subgroup by ethnicity showed that there was no significant association between p53 Arg72Pro polymorphism and thyroid cancer risk in both Caucasians and Asians. Thus, p53 Arg72Pro polymorphism may be associated with thyroid cancer risk, and ProPro genotype is likely to be a risk factor of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24037912     DOI: 10.1007/s13277-013-1078-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.

Authors:  A K Siraj; M Al-Rasheed; M Ibrahim; K Siddiqui; F Al-Dayel; O Al-Sanea; S Uddin; K Al-Kuraya
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants.

Authors:  Natassia E Bufalo; Janaina L Leite; Ana C T Guilhen; Elaine C Morari; Fabiana Granja; Ligia V M Assumpcao; Laura S Ward
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

Review 4.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

5.  Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.

Authors:  Natallia M Akulevich; Vladimir A Saenko; Tatiana I Rogounovitch; Valentina M Drozd; Eugeny F Lushnikov; Victor K Ivanov; Norisato Mitsutake; Ryo Kominami; Shunichi Yamashita
Journal:  Endocr Relat Cancer       Date:  2009-03-13       Impact factor: 5.678

Review 6.  Histone modifications and DNA double-strand break repair after exposure to ionizing radiations.

Authors:  Clayton R Hunt; Deepti Ramnarain; Nobuo Horikoshi; Puneeth Iyengar; Raj K Pandita; Jerry W Shay; Tej K Pandita
Journal:  Radiat Res       Date:  2013-02-01       Impact factor: 2.841

Review 7.  Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities.

Authors:  Neerav Goyal; Dhave Setabutr; Junaid Abdulghani; David Goldenberg
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 8.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

Review 9.  Mechanisms of programmed DNA lesions and genomic instability in the immune system.

Authors:  Frederick W Alt; Yu Zhang; Fei-Long Meng; Chunguang Guo; Bjoern Schwer
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

10.  p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.

Authors:  Yu Weng; Liqin Lu; Guorong Yuan; Jing Guo; Zhizhong Zhang; Xinyou Xie; Guangdi Chen; Jun Zhang
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

View more
  5 in total

1.  Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ankita Kumari; Charu Bahl; Navneet Singh; Digambar Behera; Siddharth Sharma
Journal:  Mol Biol Rep       Date:  2016-09-10       Impact factor: 2.316

2.  Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients.

Authors:  Roghayeh Dehghan; Mohammad Ali Hosseinpour Feizi; Nasser Pouladi; Esmaeil Babaei; Vahid Montazeri; Ashraf Fakhrjoo; Ayda Sedaei; Parvin Azarfam; Masoumeh Nemati
Journal:  Pathol Oncol Res       Date:  2014-11-20       Impact factor: 3.201

3.  p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.

Authors:  Nazanin Jalilian; Yosra Maleki; Ebrahim Shakiba; Mozafar Aznab; Ziba Rahimi; Mehdi Salimi; Zohreh Rhimi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01

4.  Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study.

Authors:  Peng Chen; Ruifen Sun; Yan Pu; Peng Bai; Fang Yuan; Yundan Liang; Bin Zhou; Yanyun Wang; Yinghe Sun; Jingqiang Zhu; Lin Zhang; Linbo Gao
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

5.  Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy.

Authors:  Daniele Lombardo; Carlo Saitta; Domenico Giosa; Francesca Casuscelli Di Tocco; Cristina Musolino; Giuseppe Caminiti; Valeria Chines; Maria Stella Franzè; Angela Alibrandi; Giuseppe Navarra; Giovanni Raimondo; Teresa Pollicino
Journal:  Oncol Lett       Date:  2020-01-22       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.